GlassScriptPhysician profile
George S Yang
NPI 1316984198
$9,319.11
in general payments reported to CMS, 2019-2025
21 companies · $2,622 in 2025
The $2,622 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $531 · 2021: $757 · 2022: $906 · 2023: $1,229 · 2024: $1,784 · 2025: $2,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,609 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,609.04 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,565.71 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Alcon Vision LLC | $1,419.08 | 2019-2025 | Rocklatan, Clareon Panoptix Pro, Tryptyr |
| Bausch & Lomb Americas INC. | $1,321.39 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $829.38 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $588.02 | 2019-2021 | |
| Oyster Point Pharma, INC. | $575.67 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $453.80 | 2024-2025 | Xdemvy |
| Amgen INC. | $420.39 | 2024-2025 | Tepezza |
| Abbvie INC. | $401.69 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Kala Pharmaceuticals, INC. | $358.40 | 2019-2022 | |
| Thea Pharma INC. | $351.16 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $267.22 | 2019-2021 | |
| Horizon Therapeutics Plc | $262.85 | 2023 | Tepezza |
| Ivantis, INC | $150.00 | 2019 | |
| Allergan, INC. | $93.27 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $88.43 | 2021-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Rxsight INC | $50.12 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Galderma Laboratories, L.P. | $40.11 | 2019 | |
| Akorn, INC. | $37.22 | 2019 | |
| Shire North American Group INC | $22.89 | 2019 | |
| Akorn Operating Company LLC | $22.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.